Premier Biomedical, Inc. (BIEL) Seeking International Patent Application for Technology to Treat Multiple Sclerosis

Premier Biomedical is a research-based company that intends to discover and develop medical treatments for a variety of disease such as multiple sclerosis, is pursuing an international patent application for its core technology to treat multiple sclerosis (MS). The company has already registered its technology in the United States and a Europe National Patent in the areas of cancer, blood sepsis, and Alzheimer’s disease, bringing the company’s patent portfolio to a total of nine provisional patent applications and six international patent applications.

Premier has structured the development of this therapy, which is functionally similar to the technology it has developed for the treatment of traumatic brain injury, cancer, and Alzheimer’s disease, to occur through the company’s existing research channels.

MS treatment is costly, with estimates that lifetime treatment of the disease costs each patient roughly $1.2 million. Premier reports that approximately 400,000 diagnosed cases of MS within the United States alone; on a worldwide basis, there are nearly 2.5 million confirmed cases of MS.

“Multiple sclerosis is a devastating disease which has destroyed the lives of many tens of thousands of patients,” Dr. Mitchell S. Felder, chairman of Premier’s Scientific Advisory Board stated in the press release. “We believe that Premier Biomedical is on the path to make a very major breakthrough in defeating this illness.”

Company president and CEO William A. Hartman noted that the company’s research and development relationships with the University of Texas at El Paso (UTEP) and the U.S. Department of Defense have increased the company’s capabilities and enabled the production of several “remarkably exciting and groundbreaking medical developments” that the company believes are positioned to advance the current medical industry.

He continued, “Our medical premise on MS and other diseases is sound: To physically remove the pathophysiologic basis of the disease via extra-corporeal means (i.e., outside the body) without potential dangerous side-effects. I invite any person or organization interested in the rapid development of an available cure for multiple sclerosis or any other major disease to reach out to Premier Biomedical to seek opportunities to participate with us in completing the R&D necessary to bring about the conversion from a laboratory cure to an available medical cure.”

For more information, visit www.premierbiomedicalinc.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net